Examkin

Soru

Zorluk: Çok zorHematology and Oncology

A 74-year-old woman is evaluated in the emergency department for the sudden onset of extensive ecchymoses over her trunk and a large, expanding hematoma on her right thigh. She has no prior personal or family history of bleeding disorders. Her past medical history is significant for rheumatoid arthritis. Vital signs are within normal limits. Laboratory studies reveal a hemoglobin of 9.4 g/dL, platelet count of 250,000/mm³, prothrombin time (PT) of 12.5 seconds (normal: 11-15 sec), and activated partial thromboplastin time (aPTT) of 78 seconds (normal: 25-35 sec). Thrombin time is normal.

Arrange the following diagnostic steps in the correct chronological sequence required to definitively diagnose and fully characterize this patient's underlying hemostatic disorder.

  1. 1Perform an immediate 1:1 mixing study with normal plasma
  2. 2Perform an incubated 1:1 mixing study at 37°C for 1 to 2 hours
  3. 3Measure specific intrinsic pathway coagulation factor activity levels (e.g., Factors VIII, IX, XI)
  4. 4Perform a Bethesda assay to quantify the specific autoantibody titer

Cevap

The correct chronological sequence is: Immediate 1:1 mixing study -> Incubated 1:1 mixing study -> Specific intrinsic pathway factor activity levels -> Bethesda assay.
The evaluation of an isolated prolonged aPTT in a patient with acute, severe bleeding requires a systematic approach. The first step is an immediate 1:1 mixing study to broadly differentiate factor deficiencies from inhibitors. Because acquired Factor VIII autoantibodies are uniquely time- and temperature-dependent, the immediate mix may falsely correct; therefore, an incubated mixing study at 37°C for 1 to 2 hours is the mandatory next step to unmask the inhibitor. Once the inhibitor pattern (failure to correct after incubation) is established, specific intrinsic factor activity levels (VIII, IX, XI) are measured to identify the exact target, which will show a markedly reduced Factor VIII level. Finally, a Bethesda assay is performed to quantify the exact titer of the Factor VIII inhibitor, which is essential for determining whether to treat the acute bleeding with high-dose Factor VIII or bypassing agents like recombinant Factor VIIa.

Adım Adım Çözüm

1
Recognize the clinical presentation of acquired hemophilia A.
The patient is an older adult with an autoimmune disease (rheumatoid arthritis) presenting with severe spontaneous bleeding and an isolated prolonged aPTT, highly suspicious for an acquired Factor VIII inhibitor.
Identifying the likely diagnosis guides the specific sequential laboratory workup for coagulation inhibitors.
2
Determine the first laboratory step to evaluate an isolated prolonged aPTT.
An immediate 1:1 mixing study with normal plasma is performed.
This differentiates a factor deficiency (aPTT corrects to normal) from an inhibitor (aPTT remains prolonged). However, acquired FVIII inhibitors often show immediate correction.
3
Address the time-dependent nature of Factor VIII inhibitors.
An incubated 1:1 mixing study at 37°C for 1-2 hours must follow.
Factor VIII autoantibodies are time- and temperature-dependent. The aPTT will prolong only after incubation, confirming the presence of this specific type of inhibitor.
4
Identify the specific target of the inhibitor.
Specific intrinsic pathway coagulation factor activity levels (VIII, IX, XI) are measured.
Once an inhibitor pattern is confirmed, measuring individual factor levels identifies which specific factor is being neutralized (Factor VIII will be selectively low).
5
Quantify the inhibitor to guide management.
A Bethesda assay is performed as the final diagnostic step.
The Bethesda assay quantifies the strength (titer) of the Factor VIII inhibitor. High titers require bypassing agents like recombinant Factor VIIa, whereas low titers may respond to high-dose Factor VIII concentrates.

Anahtar Kavram

The sequential diagnostic algorithm for acquired hemophilia A (Factor VIII inhibitor) requires an immediate mixing study, followed by an incubated mixing study to detect time-dependent inhibitors, specific factor assays to identify the target, and finally a Bethesda assay to quantify the inhibitor titer.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru